|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A novel antiviral agent whieh inhibits the endonuclease of influenza viru- ses显示文摘 | TOMASSINI JE DAVIES ME HASTINGS JC | 1996 | Antimicrob Agents Chemother1996，40，5： | 1 |
| 2 | Synthesis of natural flutimide andanalogous fully substituted pyrazine-2,6-diones, endonuclease in- hibitors of influenza virus 显示文摘 | SINGH SB TOMASSINI JE | 2001 | J Org Chem2001，66，16： | 1 |
| 3 | Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia 显示文摘 | Tomassini JE Mazzone T Goldberg RB | 2009 | Diabetes Obes Metab2009，11，9： | 1 |
| 4 | Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin,atorvastatin, or rosuvastatin compared with titrating statin monotherapy显示文摘 | Foody JM Toth PP Tomassini JE | 2013 | Vasc Health Risk Manag2013，9，28： | 1 |
| 5 | Bacterial dxpression of antibody fragments that block human rhino virus infection显示文摘 | Condra JH Sardanna VV Tomassini JE | 1990 | J Biol Chem1990，25，6： | 1 |
| 6 | Effect of Switching From Monotherapy to Combination Therapy Compared Statin With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease 显示文摘 | Le NA Tomassini JE Tershakovec AM et at | 2015 | J Am Heart Assoc2015，4，00： | 1 |
| 7 | Modeling the long-term antibody response of a human papillomavirus(HPV)virus-like particle(VLP)type 16 prophylactic vaccine显示文摘 | Fraser C Tomassini JE Xi L | | 0，，21： | 1 |
| 8 | Modeling the long-term antibody response of a human papillomavirus(HPV)virus-like particle(VLP)type 16 prophylactic vaccine显示文摘 | Fraser C Tomassini JE Xi L | | 0，，21： | 1 |
| 9 | Synthesis of natural flutimide and analogous fully Substituted pyrazine-2, 6-diones, endonuclease inhibitors of influenza virus 显示文摘 | SINGH SB TOMASSINI JE | 2001 | Org Chem2001，66，16： | 1 |
| 10 | Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine显示文摘 | Fraser C Tomassini JE Xi L | 2007 | Vaccine2007，25，21： | 1 |
| 11 | Ezetimibe: cholesterol lowering and beyond显示文摘 | BAYS HE NEFF D TOMASSINI JE | 2008 | Expert Rev Cardiovasc Ther2008，6，4： | 1 |
| 12 | Ezetimibe:cholesterol lowering and beyond显示文摘 | Bays HE Neff D Tomassini JE | | 0，，04： | 1 |
| 13 | Ezetimibe:cholesterol lowering and beyond显示文摘 | BAYS HE NEFF D TOMASSINI JE | 2008 | Expert Rev Cardiovasc Ther2008，6，4： | 1 |
| 14 | Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy 显示文摘 | Foody JM Toth PP Tomassini JE | 2013 | Vasc Health Risk Manag2013，9，： | 1 |
| 15 | Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP)type 16 prophylactic vaccine显示文摘 | Fraser C Tomassini JE Xi L | 2007 | Vaccine2007，25，21： | 1 |
| 16 | Ezetimibe :cholesterol lowering and beyond显示文摘 | Bays HE Neff D Tomassini JE | 2008 | Expert Rev Cardiovasc Ther2008，6，4： | 1 |
| 17 | Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine 显示文摘 | Fraser C Tomassini JE Xi L | 2007 | Vaccine2007，25，21： | 1 |
| 18 | Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs显示文摘 | Carroll SS Tomassini JE Bosserman M | | 0，，14： | 1 |
| 19 | Changes in LDL -C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin com- pared with titrating statin monotherapy 显示文摘 | Foody JM Toth PP Tomassini JE | 2013 | Vascular Health & Risk Management2013，9，11： | 1 |
| 20 | Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial) 显示文摘 | Grundy SM Vega GL Tomassini JE | 2011 | American Journal of Cardiology2011，188，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员